Nimesh Shah joined Domain in 2006, where he has been instrumental in investing in and helping start new medical device companies. He became a partner at Domain in 2013.
He serves as a co-founder and current board member of Zyga Technology and a board member of Benvenue Medical, Cotera, Miramar Labs, Sequent Medical, and Twelve (Foundry Newco VII), and as a board observer at Fractyl Laboratories, NeuroPace, ReVision Optics and Tandem Diabetes Care. He is also involved with The Foundry, a medical devices incubator. He had previously been involved as an observer with REVA Medical and Zogenix, both of which completed successful public offerings.
Prior to Domain, Nimesh was a part of the investment team at venture firm Cutlass Capital where he was involved with that firm’s investments in Apneon, GI Dynamics, Titan Health, and TranS1. Previous to that, Nimesh worked at Alex. Brown & Sons (now Deutsche Bank) serving as a member of the medical device equity research team.
Nimesh received his B.S. in biomedical engineering from Johns Hopkins University. While in school, he worked supporting the investment team at Alex. Brown Capital Advisory & Trust. He also spent time at Johns Hopkins Hospital involved in a project that aimed to map the functional areas of the brain.
He currently serves on the Dean’s Leadership Council for the UCSD School of Biological Sciences and as a board member for the San Diego Venture Group.